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In this paper structural and microbiological studies on the ionophorous antibiotic monensin A and its derivatives have been
collected. Monensin A is an ionophore which selectively complexes and transports sodium cation across lipid membranes, and
therefore it shows a variety of biological properties. This antibiotic is commonly used as coccidiostat and nonhormonal growth
promoter. The paper focuses on both the latest and earlier achievements concerning monensin A antimicrobial activity. The
activities of monensin derivatives, including modifications of hydroxyl groups and carboxyl group, are also presented.
1. Introduction
Ionophores are the class of compounds making complexes
with cation and then transporting it as lipid-soluble complex
across lipid bilayer. Monensin A is a representative of a
large group of naturally occurring polyether ionophorous
antibiotics. It was discovered in 1967 by Agtarap et al. [1]
as a metabolite formed in a biosynthesis of Streptomyces
cinnamonensis bacteria.The details of monensin isolation are
given in a separate work [2]. The appropriate mechanism of
action of ionophores has been presented by Pressman et al.
[3] in 1967, which marks this date as the beginning of the
chemistry of ionophores. Elucidation of the crystal structure
of monensin silver salt complex by Agtarap et al. [1], as well
as that of a crystal complex of another previously known
ionophore-nonactin with potassium cation by Kilbourn et al.
[4], has significantly contributed to the understanding of this
mechanism. Since that time a huge number of ionophorous
antibiotics have been discovered, and their structures and
antimicrobial properties have been studied. The group of
carboxylic ionophores currently consists of nearly a hundred
of compounds. However, only a few of them have been
approved for use in veterinary practice.
2. Structure of Monensin A and Its Complexes
2.1. Studies on the Monensin A Structure. Monensin A,
(Scheme 1) also called monensic acid, MONA, or MonH,
occurs as a monohydrate with a water molecule complexed
inside. The molecule of this ionophore contains six oxygen
atoms, five of which may participate in the complexation of
cations. Monensin molecule is maintained in a pseudocyclic
conformation due to the presence of bifurcated intramolecu-
lar hydrogen bonds formed between carboxyl group on one
side of themolecule and two hydroxyl groups on the opposite
side. For the first time, the crystal structure of monensic acid
monohydrate has been presented by Lutz et al. in 1971 [5].The








O formula is stabilised by
inter- and intramolecular hydrogen bonds (Figure 1(a)). This
complex crystallises from absolute ethanol in orthorhombic







Recently, Huczyński et al. have presented the crystal
structure of monensin A monohydrate obtained by crys-
tallisation from acetonitrile. In comparison to Lutz’s studies,
the new structure contains all hydrogen atoms (Figure 1(b))
[6]. Until now, no crystal form of monensic acid without
water has been presented, which could suggest that the
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Figure 1: Structure of MONAmonohydrate: (a) schematic representation [5], (b) complete crystal structure [6].
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anhydrous monensin cannot exist. Huczyński and coauthors
demonstrated that in the dichloromethane solution (DCM)
monensin A also exists as monohydrate, which has been
proved by FTIR and NMR spectroscopies.
A total synthesis of monensin was undertaken by Kishi
et al. in 1979 [15–17]. This achievement is one of the first
examples of stereoselective total synthesis through acyclic
stereocontrol. Barely a year later Still and coworkers [18–20]
presented another method for the synthesis of monensin.
2.2. Studies of theMonensinAComplexes. Ionophoretic prop-
erties of monensin A were widely studied in the last century
[21–26]. Stability constants of monensin complexes with
monovalentmetal cations such as Li+, Na+, K+, Rb+, Cs+, and
Ag+ were defined by various methods including fluorimetry,
calorimetry, relaxation, electrochemical, and 1H NMR mea-
surements. Determination of p𝐾
𝑎
values was conducted in
various protic, as well as polar aprotic solvents, and at differ-
ent temperatures. Popov and coworkers have noted thatmon-
ensin can form different types of complexes in solution, that
is, monensin metal salt called monensinates of Mon−M+ for-
mula andmonensic acid with inorganic salts ofMonH-M+X−
formula [21, 22]. Complexation titrations with other cations
have shown that the selectivity of monensin varies in the
order Ag+ > Na+ > K+ > Rb+ > Cs+ > Li+ ≈ NH
4
+ [21]. Lutz
et al. [27] have demonstrated that the ability to form com-
plexes with monovalent cations by monensin is as follows:
Na+ > K+ > Li+ > Rb+ > Cs+. A number of crystal salts of
monensinAwith different cations have been synthesized, and
their structures were studied by X-ray diffraction (see Table 1
and Figure 2) [7–14]. The structure of sodium monensinate
in chloroform solution was studied by Turner. The author
applied nuclear Overhauser effect spectroscopy to study con-
formation of this complex [28]. Full assignment of 13C and
1H NMR signals of MONA-NaCl and MONA-NaClO
4
com-
plexes in DCM solution was performed by Huczyński et al.
Three crystal complexes of monensin A with NaBr [29],
NaCl, andNaClO
4
have been synthesised [6] (Figure 3). Przy-
bylski and coauthors calculated the structures of monensin
A sodium, potassium and silver salts, monensin-free acid
monohydrate, and somemonensin derivative complexes.The
semiempirical calculations were carried out by AM1, PM3,
and PM5 parametric methods. Comparison of the calculated
parameters (bond lengths and angles) of these structures with
those in crystals has shown that the best results are achieved
by PM5 method [30].
Recently, crystal complexes of monensin with some diva-
lent metal cations have been synthesised by Pantcheva and
coworkers [31–36]. They found that three different types of
complexes can be formed, but the divalent cation is not placed
in hydrophilic cavity of the ionophore in any case. The first
type of complexes is formed with the cations such as Mg2+,







] formula, where M is divalent metal,
are neutral salts with two monensinates anions bound in a
bidentate coordination mode to the cation. The metal cation
is additionally coordinated by two water molecules placed
in axial positions of the octahedron. The crystal structure
Table 1: Chemical formula of monensin salts obtained in a crystal
form.
Number Chemical formula References
1 Li(C36H61O11) ⋅CH3CN [7]
2 Na(C36H61O11) ⋅CH3CN [8]
3 Na(C36H61O11) ⋅ 2H2O [9, 10]
4 K(C36H61O11) ⋅ 2H2O [11]
5 Rb(C36H61O11) ⋅ 2H2O [12, 13]
6 Ag(C36H61O11) [1]







] complex, which is a representative
of this type complexes is shown in Figure 4(a) [31–34]. In
the second type of complexes with such cations as Co2+,
Mn2+, and Cu2+, two molecules of monensin sodium salt are
bound with a divalent metal cation, which is simultaneously
bound with two chloride anions Figure 4(b) [35, 36]. The
complex with Hg(II) has quite a different structure in which
one cation is bound with only one molecule of monensin
(Figure 4(c)). The cation is located between carboxyl anion
and two hydroxyl groups. The twofold negative charge of the
ligand is achieved by deprotonation of carboxylic group and
secondary hydroxyl group [34].
3. Biosynthesis of Monensin A
As already mentioned, monensin was isolated for the first
time in 1967. Several homologues of it are known (Scheme 1),
but the most famous is monensin A. The isolation process
involves the biosynthesis and extraction of the monensin
sodium salt in the culture of Streptomyces cinnamonensis
actinobacteria, which is carried out in a complex medium
containing glucose, soybean oil, and grit. Cultivation process
is carried out for about a week at 30 ∘C and under intensive
aeration [37–39]. Biosynthesis ofmonensin proceeds through
the polyketide pathway with the biochemical processes sim-
ilar to those taking place in fatty acid biosynthesis. The
precursors are propionyl-CoA and malonyl-CoA, which
provide acethyl, propionyl, and butyrate units. During the
biosynthesis the following processes occur:
(i) binding of acyl groups,




(iii) reduction of ketone group,
(iv) emission of water molecule,
(v) reduction of the double bond.
In the biosynthesis performed with acetyl-CoA andmalonyl-
CoA, a multienzymatic protein complex is involved, which
plays an important role of an acyl residue carrier. The
information on the biosynthesis of monensin was obtained
through research with the use of isotopes 18O- and 13C-
labelled molecules [37]. The product of biosynthesis is
excreted from the bacterial cells, and its concentration in the
culture averages a few grams per litre. After completion of













Figure 2: Crystal structures of monensin salts with (a) Ag+ dihydrate [14], (b and c) Li+ [7], and Na+ [8] inclusion complexes with ACN
molecule, respectively, (d) Na+ [9], (e) K+ [11], and (f) Rb+ [12] dihydrates.
(a) (b) (c)
Figure 3: Crystal structures of monensin A free acid complexes with (a) NaCl, (b) NaClO
4
, and (c) NaBr [6, 29].
the biosynthesis process, the solid components are filtered
off, and the filtrate is acidified to pH 3 and then extracted
with chloroform. The extract is purified on activated carbon,
concentrated, and crystallised. If themonensin concentration
in a crude biosynthesis product is higher than 10 g/L, extrac-
tion with n-hexanol is carried out directly from this mixture.
Subsequently, a water is removed by azeotropic distillation,
and product is crystallised [37].





















, and (c) HgMon-H
2
O (protons are omitted for clarity).
4. Properties and Toxicity of Monensin A
Since its discovery, monensin A has become an object of sci-
entific interest because of its biological and pharmacological
properties. Brief characterisation and toxicity of monensin A
are presented in Table 2. At first its cellular effects on theGolgi
apparatus, both in plant and animal cells, were understood.
Monensin inhibits growth of selected cells by blocking the
intracellular transport of the Golgi apparatus proteins, with
no apparent inhibition of the synthesis of these proteins. Also,
the transfer of products formed within the Golgi structures is
inhibited by monensin [20, 40].
When exposed to monensin, the culture of plant cells
slows down their growth or selected cellular processes, and
usually the changes in functioning and structure of the Golgi
apparatus occur. However, in the animal cells monensin
induces mitochondrial damage without apparent change in
the operation of theGolgi structure [43].Monensin also slows
down and reduces the process of endocytosis, that is, trans-
port of large molecules through the cell membrane with the
participation of a peptide transporter [44, 45]. The antibiotic
induces pH change within the cellular structure, which can
lead to a reduction in the secretion and/or transportation
of the chemicals important for the proper functioning of
the cell. Monensin also affects the processes of formation
of external structures on the cell surface and their growth,
by reducing the secretion of substances responsible for these
processes (i.e., proteoglycans, collagen and procollagen, and
fibronectin) [43]. Cellular effects of monensin depend on the
body subjected to its action, the route of administration, and
the dose of this antibiotic.
The main cellular effects caused by monensin are listed
in Table 3. The very few studies performed on the antitumor
activity of monensin have demonstrated that it can inhibit
the proliferation of renal cancer cells by inducing apoptosis
in cancer cells and cell cycle arrest in G or G2-M phases [46].
5. Antimicrobial Activity of Monensin A
Monensin is one of themost widely studied ionophore antibi-
otics. Most of the work has been devoted to its biological
Table 2: Characterisation and toxicity of monensin A.








Molecular weight 670.87 g/mol
Molecular formula C36H62O11
Composition C 64,45%; H 9,32%; O 26,23%
Melting point 103–105∘C (monohydrate)
Specific rotation [𝛼]D = +47,7∘ (methanol)







activity, including the antimicrobial properties. Monensin
antibacterial activity can be explained by changes in pH and
the sodium-potassium balance in the cell, which leads to
critical disturbances in cellular processes, resulting in cell
death [47]. Monensin and some of its derivatives have shown
activity against Gram-positive bacteria of the genera Micro-
coccus, Bacillus, and Staphylococcus [35, 48, 49]. It has been
found that only Gram-positive G(+) bacteria are sensitive
to monensin, which may be due to the fact that the cell
walls of Gram-negative G(−) bacteria have more complexed
construction not permeable to large antibiotic molecules
and the complexes formed by it. The studies devoted to the
antiviral properties of monensin indicate that it is active
against some viruses. Inhibition of vesicular stomatitis and
Sindbis virus replication have been demonstrated [50, 51].
Monensin has been also found to inhibit Semliki Forest virus
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Table 3: Selected cellular effects of monensin.
Decreased secretion: proteoglycans, prolactin, albumin, transferrin,
proinsulin polypeptides, 𝛼-amylase isoenzyme, different proteins,
thyroxine-binding globulin, gonadotropin-binding globulin, acetyl
cholinesterase, phytohemagglutinin, VLD lipoproteins, and
glycoproteins of vesicular stomatitis virus
Increased secretion: catecholamines type of biogenic amines,
proteolytic cascade enzyme—cathepsin D
Damaging proteins transformation processes: changes proalbumin
into albumin
The deformation of oligosaccharides: herpes simplex virus
glycoprotein, coronaviruses, myeloperoxidase, and fibronectin
Inhibition of assimilation: horseradish peroxidase, arylsulfatase,
immunoglobulins, and 𝛼-2-macroglobulin
Inhibition of assimilated ligands dissociation: asialoglycoproteins,
asialoorosomucoid
Inhibition of ligands transfer: epidermal growth factor,
𝛽-hexosaminidase, immunoglobulins, low-density lipoprotein, and
proteoglycans to the lysosomes
Inhibition of acidification: endosomes, lysosomes, and exosomes
Impact on the processes of external cellular structures creating by
reducing the secretion: proteoglycans, collagen and procollagen,
fibronectin, and lamin
penetration into the target cells [45]. Iacoangeli and cowork-
ers have shown in their studies thatmonensin decreases DNA
synthesis, effectively inhibits the replication, and induces a
strong reduction of early viral antigens of murine polyoma
virus [52]. In vitro studies of monensin showed pronounced
activity against Plasmodium falciparum, much stronger than
that of the antimalarial drug—chloroquine. In clinical in vivo
studies in mice infected with Plasmodium vinckei petteri, a
100% animals have been cured after treatment withmonensin
doses of 10mg/kg. Antimalarial action of monensin can
be explained by impaired function of nutrient and other
vacuolar organelles of the parasite and the intracellular
acidification, which eventually lead to the cell death [53].
6. Ion Transport
It has long been known that the biological activity of mon-
ensin arises from its ability to complex with the sodium
cation and transport it across cell membranes. Initially it
was thought that the mechanism of ion transport is a simple
antiport of Na+/H+ cations [54–56]. The hypothesis assumes
that monensin molecule binds the sodium cation as a salt,
loosing proton from carboxyl group, and moves the cation
as a complex on the opposite side of the lipid membrane
(Figure 5(a)). Then, the sodium cation is released, and
carboxylate anion undergoes protonation.
A neutral acid molecule migrates back to the other side
of the membrane. This process is powered by difference of
cation concentrations inside and outside the cell and tends to
align the ions gradient. This mechanism of transport is elec-
troneutral. However, microbiological studies of monensin
A derivatives with blocked carboxyl groups such as amides
and esters have also shown their antimicrobial properties.
In 1991 Nakazato and Hatano have measured the fluxes of
Na+ and H+ using monensin A containing liposomes and
concluded that Na+ is transported in the form of a 1 : 1 com-
plex between monensic acid (MonH) and Na+ cation [57].
Recently, Huczyński et al. have synthesised two complexes
of monensin acid with NaCl and NaClO
4
and determined
their crystal structures. The authors have proven by FT-IR
study that the structure of the complexes is conserved in the
hydrophobic environment like in DCM solution [6]. These
findings support the assumption that the [MonH⋅M+X−] type
complexes can exist in hydrophobic membranes and affect
the Na+ transport also in electrogenic way (Figure 5(b)).
7. Applications of Monensin A
There are over 100 known ionophore antibiotics, but only
three, monensin, salinomycin, and lasalocid acid, have found
currently commercial application. Monensin was the first
ionophoric antibiotic approved for use by the Food and Drug
Administration (FDA) in the USA. Monensin A is an antibi-
otic which is used as coccidiostat and growth promoting
agent in veterinary practice. Due to the strong antibacterial
and coccidiostatic properties it has found application in
industrial poultry farming. Coccidia are parasitic protozoa
commonly occurring in different animal species, which mul-
tiply in the intestinal epithelial cells and propagate through
the oocysts excreted in the faeces. These microorganisms
cause inflammation of the mucous membrane of the small
intestine, resulting in diarrheal and general weakness. The
mechanism of coccidiostatic activity of monensin involves
blocking the development of trophozoites of protozoa in the
Eimeria genus of Coccicdium group, in the first phase of
schizogony. As a result, a positive effect of antibiotic on the
growth of poultry is to reduce the proliferation of parasites,
thus eliminating attenuation on stockbreeding [58, 59]. For
the prevention of coccidiosis in poultry Mondolar formula-
tion, containing 10% or 20% sodiummonensin, is used. Sub-
sequent studies have shown that monensin may also improve
food metabolism in ruminants, which ensures its better use
and, consequently, leads to faster growth of cattle. Stimulation
of growth is associated in this case with favourable changes
of intestinal bovine microflora and increasing amounts of
assimilable digested protein. Rumenesin containing 6.6% of
monensin is used as a nonhormonal growth promoter for
animals [27, 60, 61]. Monensin used as a coccidiostat in
poultry or growth promoter in cattle is relatively safe if
used in the recommended doses. However, the possibility
of poisoning animals as well as antibiotic contamination of
animal products (meat, eggs, and milk) must always be taken
into account. Due to a broad spectrum of biological activity,
monensin derivatives are an important object of research
aimed at reducing the toxicity and to obtain new compounds
with improved biological properties in terms of further use.
8. Monensin A Derivatives and Their
Antimicrobial Activity
A broad spectrum of antimicrobial and biological proper-
ties of monensin has made the chemical modification of
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1a R = CH3
1b R = CH2CH2Ph
1c R = C6H11
1d R = Ph
1e R = p − C6H4 − OPh
1f R = p − C6H4 − NO2
1g R = p − C6H4 − F
1h R = p − C6H4 − Cl
1i R = p − C6H4 − Br
1j R = p − C6H4 − I
(a) (b)
Figure 6: Structures of selected monensin A urethanes (a) [41]; crystal structure of monensin sodium urethane (b) [42].
monensin a very interesting direction of research. The novel
derivatives of the ionophore, depending on the location of
chemical modification, differ from the parent molecule in
complexation selectivity, structure of complexes formed, ion
transport mechanism, and toxicity and biological properties,
including antimicrobial activity. Several research groups have
synthesized a wide range of monensin derivatives, some of
which have been tested for antimicrobial activity.
8.1. Modifications of Hydroxyl Groups. Chemical modifica-
tion of all three hydroxyl groups has already been carried
out. Westley and coworkers have reported the synthesis and
antimicrobial properties of a series of monensin urethanes,
obtained by modification of O(XI)H group (Figure 6, com-
pounds 1a–j) [41]. These derivatives are very interesting in
terms of chemical and microbiological properties, because
they are able to transport monovalent cations about 10 times
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more effectively than monensin. The urethanes also show up
to 10-fold higher activity compared to unmodified monensin
against G(+) bacteria (MIC values varied from 0.02 to over
25 𝜇g/mL). Moreover, some of these compounds are also
active against Candida albicans fungus (MIC = 0.08 𝜇g/mL
to more than 100 𝜇g/mL for urethane, MIC > 100 𝜇g/mL
for unmodified MONA) and Penicillium digitatum (MIC
6.3 𝜇g/mL to more than 100 𝜇g/mL for urethanes, MIC >
100 𝜇g/mL for unmodified monensin).
Furthermore, four of the monensin urethanes obtained
showed antimalarial properties in in vivo tests [41]. Westley
et al. have postulated that in the molecular structure of
sodiummonensin urethanes the oxygen of urethane carbonyl
group coordinates metal cation. Recently Huczyński et al.
[42] reinvestigated the structure of the phenyl urethane of
MonNa complex and have shown that in both, solution
and crystal structure, this group does not participate in the
process of complexation (Figure 6). Chemical modification
of monensin at the C(26) carbon atomwas also carried out to
prepare various derivatives of the antibiotic including: esters,
ethers, amine, and sulphonate (Figure 7, compounds 2a–
e). Among all of these derivatives 26-fenylaminomonensin
(2c) exhibits antimicrobial activity against various bacterial
strains with MIC values of 0.20–6.25 𝜇g/mL. The activity of
this compound was higher than that of monensin and even a
very active derivative—26-phenylurethane of monensin (1d)
[62].The chemicalmodification ofmonensin at positionC-26
can also lead to changes in preferences of cation complexation
by this ionophore. Rochdi et al. [63] have demonstrated that
2d and 2emonensin derivatives cause an increase in the effec-
tive transport of potassium cation through the membrane,
whereas there is a decrease in the transport of sodium cations.
Thus, these derivatives preferentially complex and transport
potassium cations prior to sodium cations. Such inversion
of complexation selectivity by the chemical modification of
monensin has also led to improvement of its antibacterial
activity against Bacillus cereus as well as in vivo antimalarial
activity toward Plasmodium falciparum [63].
Among monensin derivatives with modified O(IV)H
hydroxyl group the ester derivatives (Figure 8, compounds
3a–e) and ether derivatives (Figure 8, compounds 4a–k) have
been synthesized [64, 65]. Acyl derivatives of monensin 3a–
e showed lower antibacterial activity against both aerobic
and anaerobic bacteria than the starting material. However,
monensin-O(4) benzyl ethers (4d–k) showed much higher
antibacterial activity than monensin. This can be related to
the hydrophobic nature of the benzyl substituent, whose role
is to improve the solubility of the derivatives of monensin in
the bacterial cell membrane [65].
8.2. Modifications of Carboxyl Group. Modifications of the
carboxyl group include the synthesis of amides and esters
of monensin A, most of which were performed by Professor
Brzezinski’s group. Recently, four new amides of monensin
have been synthesised by Łowicki et al. [66–70], and their
ability to complex monovalent metal cations such as Li+,
Na+ and K+ has been studied (Figure 9, compounds 5a–













2a R = OC(O)Ph
2b R = OCH2Ph
2c R = NHPh
2d
2e R = O
R=OSO2-𝑝C6H4Me











3a R = COCH3
3b R = COCH2CH3
3b R = COCH2CH2CH3
3b R = CO(CH2)6CH3
3e R = COPh
4a R = CH3
4b R = CH2CH = CH2
4c R = CH2CH2CH3


































































5c R = (CH2CH2O)3CH3
Figure 9: Structures of monensin amides.













pharmacological and biological effects is their ability to form
lipid-soluble pseudocyclic complexes with metal cations and
transport them through cell membranes disturbing their
natural Na+/ K+ ion balance. Thus, studies of the biological
activity of monensin derivatives should be always connected
with the studies of their ionophoretic properties.
Among all the amide complexes studied in solution, only
a complex of N-phenylamide with sodium chloride showed
a tendency to crystallize, therefore its structure has been
determined by crystallographic methods (Figure 10(a)) [66].
Moreover, 5b and 5c amides have been found to be able to
bind alkaline earth metal cations such as Mg2+, Ca2+, Sr2+,
and Ba2+ [71]. Surprisingly, the complex of 5bwith strontium
perchlorate crystallized from acetonitrile solution and its
structure has been determined (Figure 10(b)) [72]. It is worth
noting that the Sr2+ cation is placed inside the hydrophilic
cavity ofmonensin amidemolecule, which is the first example
of that kind of complex with divalentmetal cation.The ability
to complex sodium cations by two complexation centres in
monensin amide with 4-aminobenzo-15-crown-5 was inves-
tigated by spectroscopic and spectrometric methods. These
studies have proved that the Na+ cation in 1 : 1 complex is
bound in the monensin part of 5d molecule; however, the
complex of 1 : 2 stoichiometry can also be formed [70]. All
the monensin amides were tested in vitro toward G(+), G(−)
bacteria and yeasts, and they showed comparable, but a little
bit smaller activity, against G(+) cocci than that of the parent
ionophore (see Table 4).
The N-phenyl amide (5a) gave the best results in the in
vitro tests on standard strains, thus it was additionally sub-
jected to studies toward some strains of methicillin-resistant,
methicillin-susceptible S. aureus (MRSA and MSSA), and
methicillin-resistant S. epidermidis (MRSE). The 5a amid
showed significant activity against all tested hospital strains
of MRSA,MSSA, andMRSE of MIC values between 6.25 and
25 𝜇g/mL [67].
In 1988 Japanese research group led by Sakakibara synthe-
sised several amides of monensin A with chiral amino acids
(Figure 9, compounds 6a–g). Subsequently, they synthesised













7a R = H
7b R = CH3
7c R = CH2Ph
7d R = CH2C6H4OH
7e R = CH2COOH
7f R = CH2CH2COOH
Figure 11: Structures of monensylamino acid lactones.
Table 4: Minimal inhibitory concentration (MIC in 𝜇g/mL) of
monensin and its amides toward different G(+) microorganisms.
Tested strain MonA 5a 5b 5c 5d
S. aureus NCTC 4163 2 12.5 50 400 50
S. aureus ATCC 25923 1 12.5 50 400 50
S. aureus ATCC 6538 2 12.5 50 400 50
S. aureus ATCC 29213 1 12.5 50 >400 50
S. epidermidis ATCC 12228 2 12.5 100 >400 50
B. subtilis ATCC 6633 1 6.25 50 400 50
B. cereus ATCC 11778 2 6.25 25 200 25
E. hirae ATCC 10541 12.5 >400 >400 >400 400
M. luteus ATCC 9341 4 6.25 50 400 50
M. luteus ATCC 10240 2 6.25 50 200 50
Further modification of the monensylamino acids included
the lactamization reaction in which the carboxyl group of
the corresponding amino acid moiety is connected with
monensin O(XI)H hydroxyl group (Figure 11, compounds
7a–f).
The macrocyclic lactones were tested for their activity
against anaerobic bacteria and showed a lower efficiency
than that of unmodified monensin A. For example, the
values of the minimum inhibitory concentration of growth
Peptostreptococcus anaerobius strain B-30 ranged from 25 to
















8a R = CH3
8b R = CH2CH3
8c R = CH2CH2OH
8d R = CH2CH2OCH3
8e R = CH2CH2OCH2CH2OH
8f R = CH2CH2OCH2CH2OCH3
8g R = CH2CH2OCH2CH2OCH2CH2OCH3
8h R = CH2 CH2
8l R = CH2
8i R = CH2
8j R = CH2
8k R = CH2CH2
NO2
8m R = H2C









O] and (b) [8m—NaClO
4
] complexes.
Figure 14: Ball and stick projection of the proton channel structure made up of eight (8a + 3H
2
O) species calculated by the PM5 method.
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Table 5: Minimal inhibitory concentration of monensin and its
esters toward different G(+) microorganisms.
Tested strain MonH 8k 8h 8g
S. aureus NCTC 4163 2 100 100 12.5
S. aureus ATCC 25923 1 100 50 6.25
S. aureus ATCC 6538 2 100 100 12.5
S. aureus ATCC 29213 1 100 50 6.25
S. epidermidis ATCC 12228 2 100 100 12.5
B. subtilis ATCC 6633 1 12.5 25 6.25
B. cereus ATCC 11778 2 12.5 50 6.25
E. hirae ATCC 10541 12.5 >400 >400 50
M. luteus ATCC 9341 4 100 200 25
M. luteus ATCC 10240 2 50 50 12.5
C. albicans ATCC 10231 ia ia ia 200
C. albicans ATCC 90028 ia ia ia 200
C. parapsilosis ATCC 22019 ia ia ia 400
ia: inactive compound.
50𝜇g/mL for compounds 7a–f, whereas theMIC value for the
monensin was 1.56𝜇g/mL [74].
The largest group of monensin A derivatives are esters,
most of which have been synthesised by Huczyński et al.
during the last decade (Figure 12, compound 8a–m). The
ability of the esters to form complexes withmonovalent alkali
[75–82] as well as divalent alkaline earth metal cations [83–
85] has been investigated.
Two complexes of monensin esters have been obtained
in crystal form, that is, aqualithium 1-naphthylmethyl
ester of monensin perchlorate (Figure 13(a)) [86], and 1-
naphthylmethyl ester of monensin with sodium perchlorate
(Figure 13(b)) [87].
An interesting case is monensin methyl ester (8a) which
is able to form a proton channel created by eight molecules
of 8a each with three water molecules bounded in the
hydrophilic space. Within the channel all 24 water molecules
are connected by almost linear hydrogen bonds (Figure 14)
[88]. The H+ cation can be attached on one side of the
channel, while the other proton is dissociated on the opposite
side of the channel.These studies show thatmonensinmethyl
ester can be recognised as a channel forming ionophore,
while unmodified monensin is considered to be the typical
ion carrier.
Antimicrobial properties of all the esters 8a–m have been
tested towards G(+), G(−) bacteria and yeasts [49]. Among
the wide range of these derivatives only three (8h, 8g, and 8k)
have shown activity against some strains of Gram-positive
bacteria.
Monensin A and its esters, which showed activity
against the strains of Gram-positive cocci, were subjected
to additional testing on hospital strains of S. aureus, includ-
ing methicillin-susceptible (MSSA) and methicillin-resistant
(MRSA) strains.
These studies have indicated that monensin and 2-
morpholinoethyl ester (8k) show high activity against both
types of S. aureus, that is, MRSA and MSSA. The other two
esters (8h and 8g) show moderate activity. The MIC values
of the monensin esters are compared with that of unmodified
monensin in Table 5.
In the Professor Brzezinski’s group the synthesis of
macromolecular derivatives of monensin (dimers and
trimers) has also been developed. These derivatives are
completely inactive against Gram-negative bacteria, because
the compounds with high-molar masses are unable to
penetrate the membrane of these bacteria. However, these
compounds showed moderate activity in the assays against
Gram-positive bacteria, their MIC values for G(+) bacteria
ranged from 6.25 𝜇g/mL to 200𝜇g/mL [89].
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[6] A. Huczyński, J. Janczak, D. Łowicki, and B. Brzezinski, “Mon-
ensin A acid complexes as a model of electrogenic transport of
sodium cation,” Biochimica et Biophysica Acta, no. 9, pp. 2108–
2119, 1818.
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[42] A. Huczyński, M. Ratajczak-Sitarz, J. Stefańska, A. Katrusiak,
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